Updating results

7 results for Dinutuximab Sort: Relevance | Date

Dinutuximab beta for treating neuroblastoma (TA538)

Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over

Technology appraisal guidance Published August 2018

Neurological conditions

Everything NICE has said on neurological conditions in an interactive flowchart

NICE Pathway Published March 2014 Last updated March 2019

Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]

In development [GID-TAG507] Expected publication date: TBC

Technology appraisal guidance In development

Past appeals and decisions

syndrome - azacitidine 1 June 2010 TBC Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) 30 September 2016 TA494...

Published January 2019

Block scoping reports

NICE block scoping reports

Published January 2019

Cancer drug for children recommended after becoming cost effective for NHS patients

Around 60% of children with high-risk neuroblastoma could be treated with dinutuximab beta

News Published July 2018

Long term benefit of neuroblastoma treatment is too uncertain, says NICE

NICE has published draft guidance in which dinutuximab beta is not recommended as a treatment for high-risk neuroblastoma – a rare type of cancer that mainly affects children and young people.

News Published May 2018